Alvostat

Primary hypercholesterolaemia & mixed dyslipidaemia (including Fredrickson Type IIa, IIb; heterozygous familial hypercholesterolaemia) as an adjunct to diet when response to diet & exercise is inadequate. Primary dysbetalipoproteinaemia (Fredrickson Type III hyper lipoproteinaemia) as an adjunct to diet when response to diet & exercise is inadequate. Reduces elevated LDL-C, total-C & triglycerides; increases HDL-C; lowers ApoB, non-HDL-C, VLDL-C, VLDL-TG, LDL-C/HDL-C, total-C/HDL-C, non-HDL-C/HDL-C, ApoB/ApoA-I ratios & increases ApoA-I. Homozygous familial hypercholesterolaemia, either alone or as an adjunct to diet & other lipid-lowering treatments (eg, LDL apheresis). Primary prevention of CV disease; individuals w/o clinically evident CHD but w/ an increased risk of CV disease based on age ≥50 yr in men & ≥60 yr in women, hsCRP ≥2 mg/L, & presence of at least 1 additional CV disease risk factor (eg, HTN, low HDL-C, smoking, or family history of premature CHD). Reduce risk of stroke, MI, arterial revascularization procedures. Childn & adolescents 10-17 yr; as an adjunct to diet to reduce total-C, LDL-C & ApoB levels in adolescent boys & girls, who are at least 1 yr postmenarche, 10-17 yr of age w/ heterozygous familial hypercholesterolaemia if after an adequate trial of diet therapy the following findings are present: LDL-C >190 mg/dL or >160 mg/dL & there is +ve family history of premature CV disease or ≥2 other CV disease risk factors.

Individualized dosage. Statin naive patient; switch from another HMG CoA reductase inhibitor Initially 5 or 10 mg once daily. Adjustments to next dose level can be made after 4-6 wk if necessary. Severe hypercholesterolaemia at high CV risk particularly familial hypercholesterolaemia Increasing the dose to 40 mg should be reversed. Asian patient Initially 5 mg once daily should be considered. Patient known to have c.521CC or c.421AA genotype Max: 20 mg once daily. Paed patient Familial hypercholesterolemia Initially 5 mg once daily. Max daily dose: 10 mg. Adjustments should be made at intervals of ≥4 wk.

May be taken with or without food.

Hypersensitivity. Active liver disease or unexplained, persistent elevations of serum transaminases. Concomitant use w/ ciclosporin. Severe renal impairment (CrCl <30 mL/min) Women of child-bearing potential not using appropriate contraceptive measures. Pregnancy & lactation.

Dyslipidaemic Agents

C10AA07 - rosuvastatin ; Belongs to the class of HMG CoA reductase inhibitors. Used in the treatment of hyperlipidemia.

POM